Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

NCT05200286 is registered in ClinicalTrials.gov with F2G Biotech GmbH as lead sponsor.

NCT NCT05200286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05200286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
Lead sponsor
F2G Biotech GmbH
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2022
Completion date
December 13, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment